TY - JOUR
T1 - Research priorities for atrial fibrillation in Australia
T2 - a statement from the Australian Cardiovascular Alliance clinical arrhythmia theme
AU - Elliott, Adrian D.
AU - Middeldorp, Melissa E.
AU - McMullen, Julie R.
AU - Fatkin, Diane
AU - Thomas, Liza
AU - Gwynne, Kylie
AU - Hill, Adam P.
AU - Shang, Catherine
AU - Hsu, Meng-Ping
AU - Vandenberg, Jamie I.
AU - Kalman, Jonathan M
AU - Sanders, Prashanthan
AU - Australian Cardiovascular Alliance (ACvA) Atrial Fibrillation Working Group
N1 - Crown Copyright 2024. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.
PY - 2024/11
Y1 - 2024/11
N2 - Atrial fibrillation (AF) is highly prevalent in the Australian community, ranking amongst the highest globally. The consequences of AF are significant. Stroke, dementia and heart failure risk are increased substantially, hospitalisations are amongst the highest for all cardiovascular causes, and Australians living with AF suffer from substantial symptoms that impact quality of life. Australian research has made a significant impact at the global level in advancing the care of patients living with AF. However, new strategies are required to reduce the growing incidence of AF and its associated healthcare demand. The Australian Cardiovascular Alliance (ACvA) has led the development of an arrhythmia clinical theme with the objective of tackling major research priorities to achieve a reduction in AF burden across Australia. In this summary, we highlight these research priorities with particular focus on the strengths of Australian research and the strategies needed to move forward in reducing incident AF and improving outcomes for those who live with this chronic condition.
AB - Atrial fibrillation (AF) is highly prevalent in the Australian community, ranking amongst the highest globally. The consequences of AF are significant. Stroke, dementia and heart failure risk are increased substantially, hospitalisations are amongst the highest for all cardiovascular causes, and Australians living with AF suffer from substantial symptoms that impact quality of life. Australian research has made a significant impact at the global level in advancing the care of patients living with AF. However, new strategies are required to reduce the growing incidence of AF and its associated healthcare demand. The Australian Cardiovascular Alliance (ACvA) has led the development of an arrhythmia clinical theme with the objective of tackling major research priorities to achieve a reduction in AF burden across Australia. In this summary, we highlight these research priorities with particular focus on the strengths of Australian research and the strategies needed to move forward in reducing incident AF and improving outcomes for those who live with this chronic condition.
KW - Atrial fibrillation
KW - Mechanisms
KW - Electrophysiology
KW - Catheter ablation
KW - Prevention
KW - Genetics
UR - http://www.scopus.com/inward/record.url?scp=85203238841&partnerID=8YFLogxK
U2 - 10.1016/j.hlc.2024.08.008
DO - 10.1016/j.hlc.2024.08.008
M3 - Article
C2 - 39244450
SN - 1443-9506
VL - 33
SP - 1523
EP - 1532
JO - Heart, Lung and Circulation
JF - Heart, Lung and Circulation
IS - 11
ER -